Alumis Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2

– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose –

United statesSan diegoTeri dahlmanKim pappMartin bablerAlumis incRed house communicationsProbity medical researchAmerican academy of dermatologyAmerican academyAnnual meetingPsoriasis areaSeverity scoreAlumi chief medicalChief executive officerOpen label extension

Alumis Presents Positive Data from Phase 2 Clinical Trial

Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024..

United statesSan diegoKim pappMartin bablerTeri dahlmanProbity medical researchAmerican academy of dermatologyAlumis incRed house communicationsAmerican academyAnnual meetingPsoriasis areaSeverity scoreAlumi chief medicalChief executive officerTrialand open label extension

Alumis Presents Positive Data From Phase 2 Clinical Trial Of ESK-001, An Oral Allosteric TYK2 Inhibitor For The Treatment Of Plaque Psoriasis, At AAD

Alumis Presents Positive Data From Phase 2 Clinical Trial Of ESK-001, An Oral Allosteric TYK2 Inhibitor For The Treatment Of Plaque Psoriasis, At AAD
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoKim pappMartin bablerAmerican academy of dermatologyAlumis incProbity medical researchAmerican academyAnnual meetingPsoriasis areaSeverity scoreAlumi chief medical officerChief executive officer

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoTeri dahlmanMartin bablerKim pappAmerican academy of dermatologyProbity medical researchRed house communicationsAlumis incPresents positive dataOral allostericPlaque psoriasisAmerican academyAnnual meetingPsoriasis areaSeverity score

Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis

Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomMaura gavaghanMartin bablerAlumis incIsles lupus assessment groupAnnounces expansionSystemic lupus erythematosusCombined lupus assessmentAlumi phaseForesite labsRed house consulting